That doesn't change facts, entire sector is down, no one is buying this, total fraud. The worst aquisition in HISTORY of an OVERVALUED BIOTECH BUBBLE RECEPTOS!
u crack me up this company had great eaarnings and forward guidance and u wonder why its held up lmao
As I was going over the call today something dawned on me, and I just had to share it becuase it is very awesome. We all know about Celgene in Hematology and Oncology. What I realized was the Inflammation and Immunology part. Let me go over this so it is laid out good.
We have Revelmid that should reach 7 to 9 Billion in sales at peak. Abraxane with 1.5 to 2 Billion in peak sales. Pomalyst with 2 Billion in sales. CC-486 with sale of up to 4 Billion by my calculations. This brings the H&O franchise to around 14 to 15 Billion in sales by 2024. I think they estimated it would reach close to 14 Billion by 2020, but I am conservative. This doesnt count any of the partner drugs either.
Now lets look at I&I which is where I put together this pattern. Celgene is targeting Humira which is one of the biggest all time block buster drugs with over 17 Billion in sales. Humira will go off patten starting in 2017 and 2018. With Otezla's 2 Billion in sales, GED-301 (Morgasen) with 5-7 Billion in sales, and RPC-1063 from Receptos with 4-6 Billion in sales. Celgene will have captured nearly 80% of Humira's sales by 2024. This could bring the I&I franchise up to 15B in totals sales.
Celgene could reach 28 to 30 Billion in revenues by 2024 which is just prior to Revlimid going off patent in 2024 - 2027. After 2024 would be the time of issue. Even if Celgene has a drug big enough to offset Revlimid fading out, it could be a few years where earnings and revenues move sideways. I have said, I plan to stay in Celgene till 2020. By then we should know if the pipline will be strong enough to offset Revlimid going off patent.
just what I thought celg moves guidance up and buying recept tells the bears we aren't a one trick pony that was what kyle bass was doing shorting the stock and attacking revlamint just another bear #$%$ tactic
That the rest of Wall Street is finally seeing what I saw in CELG for these past 2 years. Not that I am complaining since the stock is up around 200+%. I just found it odd that not 2 months ago when CELG announced at DDW that GED-301 could be worth 7B in revenues, no one even cared. I remember last July, after they bought this asset, I said it could be as big as Revlimid. Now suddenly the RCPT deal seems to be the tipping point where they could no longer deny CELG's greatness. I am glad that the market is finally giving CELG the respect it is due especially since April and May were some tough months to be long CELG and it was even harder to be buying to the fear of the patent hearing in May. I plan to be long CELG for at least another 5 years. I will have to wait for the next big correction to put back on my trading position. It has been the best stock I have owned over the past 2 years and I managed to nearly double the returns of the stock by trading around my core position. Congrats to all my fellow share holders who didn't panic and sell back in April and May. And please someone get Kyle Bass a tissue. I think he is going to need it lol.
receptos has made celg more than a one trick pony diversication makes this company muchg stronger the bears want to beat this down as always but thee recpt deal changes everything
That is GAAP EPS, so it should reflect costs associated with all of the partnerships/acquisitions that CELG has announced recently. CELG considers such expenses one-time costs so it does not include them in non-GAAP EPS. Non-GAAP EPS estimates were raised from 4.60-4.75 to 4.75-4.85. So CELG predicts more cash flows, but a big chunk of that cash will be put towards partnerships and acquisitions. It's not a bad thing, assuming that some of those deals lead to successful products.
See news / earings report.
"GAAP diluted EPS is expected to be in the range of $2.17 to $2.46, lowered from the original range of $2.97 to $3.19."
? ? ? ? ? ?